甘精胰岛素联合瑞格列奈治疗2型糖尿病的疗效研究  

Study on efficacy of insulin glargine combined with repaglinide in the treatment of type 2 diabetes mellitus

作　　者：许红莲 黎月琴 XU Hong-lian;LI Yue-qin(Department of Cardiovascular Endocrinology,Beitun Hospital of the 10th Division of Production and Construction Corps of Xinjiang Uygur Autonomous Region,Uygur 836000,China)

机构地区：[1]新疆维吾尔自治区生产建设兵团第十师北屯医院心血管内分泌科,836000

出　　处：《中国实用医药》2023年第18期21-25,共5页China Practical Medicine

摘　　要：目的研究2型糖尿病应用瑞格列奈联合甘精胰岛素治疗的疗效。方法184例2型糖尿病患者,依据用药方法不同分为联合用药组和单独用药组,每组92例。联合用药组患者采用瑞格列奈联合甘精胰岛素治疗,单独用药组采用单独预混胰岛素治疗。比较两组用药前后体质量指数、血糖指标(糖化血红蛋白、空腹血糖、餐后2 h血糖)、24 h尿蛋白定量、生活质量及临床疗效、日胰岛素用量、血糖达标时间、低血糖发生情况、不良反应发生情况、治疗满意度。结果用药后,两组患者的体质量指数、糖化血红蛋白、空腹血糖、餐后2 h血糖、24 h尿蛋白定量均低于本组用药前,生活质量评分均高于本组用药前,且联合用药组患者的体质量指数(22.12±3.05)kg/m2、糖化血红蛋白(6.30±0.61)%、餐后2 h血糖(7.85±1.33)mmol/L、空腹血糖(5.62±1.14)mmol/L、24 h尿蛋白定量(119.25±10.77)mg/24 h均低于单独用药组(25.36±2.75)kg/m2、(7.63±0.20)%、(9.44±0.20)mmol/L、(7.13±0.33)mmol/L、(178.23±10.58)mg/24 h,生活质量评分(81.23±9.22)分高于单独用药组的(68.45±9.26)分,差异具有统计学意义(P<0.05)。联合用药组患者的总有效率为93.48%(86/92),高于单独用药组的76.09%(70/92),差异具有统计学意义(P<0.05)。联合用药组患者的日胰岛素用量(16.02±2.45)U/d少于单独用药组的(33.05±5.67)U/d,血糖达标时间(6.32±1.05)d短于单独用药组的(7.23±1.28)d,低血糖发生率2.17%(2/92)低于单独用药组的10.87%(10/92),差异具有统计学意义(P<0.05)。联合用药组患者的不良反应发生率为6.52%(6/92),低于单独用药组的23.91%(22/92),差异具有统计学意义(P<0.05)。联合用药组患者的治疗满意度为97.83%(90/92),高于单独用药组的78.26%(72/92),差异具有统计学意义(P<0.05)。结论2型糖尿病采用瑞格列奈联合甘精胰岛素治疗的疗效较单独预混胰岛素治疗显著。Objective To study the efficacy of insulin glargine combined with repaglinide in the treatment of type 2 diabetes mellitus.Methods A total of 184 patients with type 2 diabetes mellitus were divided into combined medication group and single medication group according to different medication methods,with 92 cases in each group.The combined medication group was treated with repaglinide and insulin glargine,and the single medication group was treated with premixed insulin alone.Both groups were compared in terms of body mass index,blood glucose index(glycosylated hemoglobin,fasting blood glucose,2-h postprandial blood glucose),24-h urinary protein quantification and quality of life before and after treatment,clinical efficacy,daily insulin dosage,blood glucose compliance time,occurrence of hypoglycemia,occurrence of adverse reactions,and treatment satisfaction.Results After treatment,the body mass index,glycosylated hemoglobin,fasting blood glucose,2-h postprandial blood glucose and 24-h urinary protein quantification in both groups were lower than those before treatment in this group,and the quality of life score was higher than that before treatment in this group;in combined medication group,the body mass index was(22.12±3.05)kg/m2,the glycosylated hemoglobin was(6.30±0.61)%,the 2 h postprandial blood glucose was(7.85±1.33)mmol/L,the fasting blood glucose was(5.62±1.14)mmol/L,and the 24-h urinary protein quantification was(119.25±10.77)mg/24 h,which were lower than those of(25.36±2.75)kg/m2,(7.63±0.20)%,(9.44±0.20)mmol/L,(7.13±0.33)mmol/L,and(178.23±10.58)mg/24 h in single medication group;the quality of life score of(81.23±9.22)points in combined medication group was higher than that of(68.45±9.26)points in single medication group;the differences were statistically significant(P<0.05).The total effective rate of combined medication group was 93.48%(86/92),which was higher than that of 76.09%(70/92)of single medication group,and the difference was statistically significant(P<0.05).The daily insulin dosa

关 键 词：2型糖尿病 预混胰岛素 瑞格列奈 甘精胰岛素 体质量指数 血糖 日胰岛素用量 低血糖 不良反应 

分 类 号：R587.1[医药卫生—内分泌]